Ligelizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ligelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIGHE
Clinical data
SynonymsQGE031
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6534H10000N1716O2038S44
Molar mass146.6 kDa g·mol−1

Ligelizumab (QGE031) (INN) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It binds to IGHE an acts as an immunomodulator.[2]

This drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials.

Adverse drug effects[edit]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ligelizumab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).